Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McClellan on inpatient rule

This article was originally published in The Gray Sheet

Executive Summary

"We are acutely aware of the disruptions that could occur if major changes are made too quickly or inappropriately," writes CMS Administrator Mark McClellan in a July 20 letter to Sen. Rick Santorum (R-Pa.). He notes that the final inpatient payment system rule, due out Aug. 1, "will reflect modifications as appropriate to achieve the goal of smooth and effective implementation." The letter is in response to comments signed by 53 senators and 189 representatives urging a one-year delay to proposed changes to the system that would switch to cost-based payments and adjust diagnosis-related groups for illness severity (1"The Gray Sheet" July 17, 2006, p. 6)...

You may also be interested in...



Senate, House Members Weigh In On Delay Of Inpatient Payment Overhaul

Device makers hope Senate Finance Committee Chair Charles Grassley (R-Iowa) can sway CMS to delay overhaul of inpatient payments until fiscal year 2008 with his long-awaited comments to the agency

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
UsernamePublicRestriction

Register

MT023803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel